JP2022508513A5 - - Google Patents

Info

Publication number
JP2022508513A5
JP2022508513A5 JP2021542070A JP2021542070A JP2022508513A5 JP 2022508513 A5 JP2022508513 A5 JP 2022508513A5 JP 2021542070 A JP2021542070 A JP 2021542070A JP 2021542070 A JP2021542070 A JP 2021542070A JP 2022508513 A5 JP2022508513 A5 JP 2022508513A5
Authority
JP
Japan
Prior art keywords
day
compound
administered
pharmaceutically acceptable
cocrystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021542070A
Other languages
English (en)
Japanese (ja)
Other versions
JP7466549B2 (ja
JP2022508513A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053721 external-priority patent/WO2020072334A1/en
Publication of JP2022508513A publication Critical patent/JP2022508513A/ja
Publication of JP2022508513A5 publication Critical patent/JP2022508513A5/ja
Application granted granted Critical
Publication of JP7466549B2 publication Critical patent/JP7466549B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021542070A 2018-10-01 2019-09-30 がん治療のための併用療法 Active JP7466549B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862739809P 2018-10-01 2018-10-01
US62/739,809 2018-10-01
US201862773980P 2018-11-30 2018-11-30
US62/773,980 2018-11-30
PCT/US2019/053721 WO2020072334A1 (en) 2018-10-01 2019-09-30 Combination therapy for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2022508513A JP2022508513A (ja) 2022-01-19
JP2022508513A5 true JP2022508513A5 (cg-RX-API-DMAC7.html) 2022-10-13
JP7466549B2 JP7466549B2 (ja) 2024-04-12

Family

ID=69945395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021542070A Active JP7466549B2 (ja) 2018-10-01 2019-09-30 がん治療のための併用療法

Country Status (11)

Country Link
US (3) US11529339B2 (cg-RX-API-DMAC7.html)
EP (1) EP3860610A4 (cg-RX-API-DMAC7.html)
JP (1) JP7466549B2 (cg-RX-API-DMAC7.html)
CN (1) CN112839658B (cg-RX-API-DMAC7.html)
AU (1) AU2019351811B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021006318A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114401A1 (cg-RX-API-DMAC7.html)
IL (1) IL281845B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003842A (cg-RX-API-DMAC7.html)
SG (1) SG11202103141YA (cg-RX-API-DMAC7.html)
WO (1) WO2020072334A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3114401A1 (en) 2018-10-01 2020-04-09 Celgene Corporation Combination therapy for the treatment of cancer
KR20220110243A (ko) * 2019-12-02 2022-08-05 셀진 코포레이션 암의 치료를 위한 요법
CN115916191B (zh) * 2020-06-25 2026-06-23 新基公司 用组合疗法治疗癌症的方法
US20260098035A1 (en) 2022-09-20 2026-04-09 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
WO2025195464A1 (zh) * 2024-03-21 2025-09-25 上海惠康济民生物医药技术有限公司 取代的异吲哚啉类化合物、制备方法、药物组合物及应用
CN119161336B (zh) * 2024-07-24 2025-09-05 四川大学 一种作为Blimp1抑制剂的小分子化合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681633C (en) 2007-03-20 2018-01-09 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
TWI509247B (zh) 2010-03-12 2015-11-21 西建公司 利用雷那度胺(lenalidomide)治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記
SI2683384T1 (sl) 2011-03-11 2016-05-31 Celgene Corporation Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona
HK1211577A1 (en) 2012-08-09 2016-05-27 细胞基因公司 Processes for the preparation of (s)-3-4- ((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
LT2882737T (lt) 2012-08-09 2019-04-25 Celgene Corporation (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diono hidrochlorido kieta forma
KR20210073616A (ko) 2012-08-09 2021-06-18 셀진 코포레이션 면역-관련 및 염증성 질환의 치료
UA116544C2 (uk) 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
US20140343058A1 (en) 2012-08-09 2014-11-20 Celgene Corporation Treatment of systemic lupus erythematosus
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
TWI745271B (zh) 2014-05-19 2021-11-11 美商西建公司 全身紅斑性狼瘡之治療
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US11124577B2 (en) * 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
CA3114401A1 (en) 2018-10-01 2020-04-09 Celgene Corporation Combination therapy for the treatment of cancer
EA202190865A1 (ru) * 2018-11-30 2021-07-01 Селджин Корпорейшн Комбинированная терапия для лечения рака

Similar Documents

Publication Publication Date Title
US10632112B2 (en) Combination therapy for treatment of HBV infections
US12077554B2 (en) CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2022537551A5 (cg-RX-API-DMAC7.html)
TWI633887B (zh) 用於預防及/或治療多囊性腎臟病之藥物
US10583129B2 (en) Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
JP2018531605A5 (cg-RX-API-DMAC7.html)
JP2024546605A (ja) がんを治療するための併用療法の使用
JP2020523317A5 (cg-RX-API-DMAC7.html)
RU2358730C2 (ru) Производное эпотилона для лечения гепатомы и других раковых заболеваний
JP2020515523A5 (cg-RX-API-DMAC7.html)
CN1181819C (zh) 使用五氟苯磺酰胺的综合疗法
EP4349341A1 (en) Pharmaceutical preparation for preventing or treating pulmonary fibrosis
CN118946371A (zh) 靶向psma的放射性药物和检查点抑制剂的组合疗法
JP2023011549A (ja) クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬
CN105616411A (zh) 治疗结肠癌的组合物及其应用
US20220296557A1 (en) Combinations of bcl-2/bcl-xl inhibitors and related uses
CN1711090A (zh) 用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合
JP2019038858A (ja) ペマフィブラートを含有する医薬
JP2024505515A5 (cg-RX-API-DMAC7.html)
TW201618777A (zh) 脂質異常症治療劑
CN102869353A (zh) 自身免疫疾病的治疗
JP2016210688A (ja) 放射性抗腫瘍剤、及び、抗腫瘍用キット
WO2021217084A1 (en) Use of nitro-fatty acids and analogues thereof for the prevention and/or treatment of acute lung injury and/or sars-cov-2 infection
RU2008111064A (ru) Кристаллические формы дельта и ипсилон иматинибмезилата
HK1225968B (en) Combination therapy for treatment of hbv infections